AEGERION PHARMACEUTICALS A NOVELION THERAPEUTICS COMPANY for AEGERION PHARMACEUTICALS A NOVELION THERAPEUTICS COMPANY
A later version of this report replaces this one, so LegiList's totals use the current version instead. This page shows this version exactly as filed.
Versions of this report
Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.
| Filing | Filed | Amount | Counted |
|---|---|---|---|
| 4th Quarter - Report (this page) | Jan 19, 2018 | $75,000 | Replaced |
| 4th Quarter - Termination | Jul 27, 2018 | $75,000 | Yes |
What was lobbied
One issue area, each in the filer's own words, with who lobbied on it and where.
Health Issues HCR
Health Care Reform Rare Diseases Medicare and Medicaid
Foreign entity interest: That the policy climate in the US continues to support ultra-rare disease patient access to therapies in their healthcare coverage.
| Lobbyist | Covered position, as disclosed |
|---|---|
| MICHAEL J EGING | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.